Medesis Pharma S.A. (ALMDP.PA)
EUR 0.34
(-2.86%)
EUR 0.34
(-2.86%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 1.15 Million EUR | 7.67% |
| 2022 | 1.07 Million EUR | -1.74% |
| 2021 | 1.09 Million EUR | 1778.33% |
| 2020 | -65.23 Thousand EUR | -103.82% |
| 2019 | 1.7 Million EUR | 19.54% |
| 2018 | 1.42 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q2 | 1.06 Million EUR | -55.7% |
| 2023 FY | 1.15 Million EUR | 7.67% |
| 2023 Q4 | 1.15 Million EUR | -56.09% |
| 2023 Q3 | 2.63 Million EUR | 148.56% |
| 2023 Q1 | 2.39 Million EUR | 122.65% |
| 2022 Q4 | 1.07 Million EUR | 0.0% |
| 2022 Q3 | 1.07 Million EUR | 14.08% |
| 2022 FY | 1.07 Million EUR | -1.74% |
| 2022 Q2 | 942.96 Thousand EUR | 0.0% |
| 2022 Q1 | 942.96 Thousand EUR | -13.87% |
| 2021 Q3 | 1.09 Million EUR | 4341.58% |
| 2021 Q2 | 24.64 Thousand EUR | 0.0% |
| 2021 Q1 | 24.64 Thousand EUR | 137.79% |
| 2021 Q4 | 1.09 Million EUR | 0.0% |
| 2021 FY | 1.09 Million EUR | 1778.33% |
| 2020 Q2 | 2.01 Million EUR | 0.0% |
| 2020 FY | -65.23 Thousand EUR | -103.82% |
| 2020 Q4 | -65.23 Thousand EUR | -105.35% |
| 2020 Q3 | 1.22 Million EUR | -39.56% |
| 2019 FY | 1.7 Million EUR | 19.54% |
| 2018 FY | 1.42 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | -714 Thousand EUR | 262.214% |
| ABIVAX Société Anonyme | -196.47 Million EUR | 100.589% |
| Adocia SA | 127 Thousand EUR | -811.976% |
| Aelis Farma SA | -16.19 Million EUR | 107.153% |
| Biophytis S.A. | 2.7 Million EUR | 57.151% |
| Advicenne S.A. | 12.17 Million EUR | 90.487% |
| genOway Société anonyme | 2.97 Million EUR | 61.042% |
| IntegraGen SA | -709.74 Thousand EUR | 263.186% |
| Neovacs S.A. | -237.08 Thousand EUR | 588.517% |
| NFL Biosciences SA | -2.27 Million EUR | 150.891% |
| Plant Advanced Technologies SA | 4.35 Million EUR | 73.414% |
| Quantum Genomics Société Anonyme | -830.54 Thousand EUR | 239.451% |
| Sensorion SA | 1.37 Million EUR | 15.963% |
| Theranexus Société Anonyme | 2.44 Million EUR | 52.613% |
| TME Pharma N.V. | -1.07 Million EUR | 207.341% |
| Valbiotis SA | -18.13 Million EUR | 106.385% |
| TheraVet SA | 12.78 Thousand EUR | -8959.132% |
| Valerio Therapeutics Société anonyme | 2.18 Million EUR | 46.871% |
| argenx SE | -1.83 Billion EUR | 100.063% |
| BioSenic S.A. | 28.04 Million EUR | 95.87% |
| Celyad Oncology SA | -6.1 Million EUR | 118.981% |
| DBV Technologies S.A. | -114.95 Million USD | 101.008% |
| Galapagos NV | -157.2 Million EUR | 100.737% |
| Genfit S.A. | -7.61 Million EUR | 115.218% |
| GeNeuro SA | 5.91 Million EUR | 80.404% |
| Hyloris Pharmaceuticals SA | -25.11 Million EUR | 104.612% |
| Innate Pharma S.A. | -30.71 Million EUR | 103.771% |
| Inventiva S.A. | 10.48 Million EUR | 88.958% |
| MaaT Pharma SA | -10.2 Million EUR | 111.349% |
| MedinCell S.A. | 39.5 Million EUR | 97.068% |
| Nanobiotix S.A. | -24.71 Million EUR | 104.686% |
| Onward Medical N.V. | -12.89 Million EUR | 108.983% |
| Oryzon Genomics S.A. | 1.43 Million EUR | 19.025% |
| OSE Immunotherapeutics SA | 27.12 Million EUR | 95.731% |
| Oxurion NV | 10.71 Million EUR | 89.186% |
| Pharming Group N.V. | 99.4 Million EUR | 98.835% |
| Poxel S.A. | 44.55 Million EUR | 97.401% |
| GenSight Biologics S.A. | 16.29 Million EUR | 92.892% |
| Transgene SA | -14.4 Million EUR | 108.038% |
| Financière de Tubize SA | 78.62 Million EUR | 98.527% |
| UCB SA | 2.17 Billion EUR | 99.947% |
| Valneva SE | 82.73 Million EUR | 98.6% |
| Vivoryon Therapeutics N.V. | -18.52 Million EUR | 106.252% |